BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32372309)

  • 1. Long-term outcome of surgical resection in patients with gastroenteropancreatic neuroendocrine neoplasia: results from a German nation-wide multi-centric registry.
    Begum N; Maasberg S; Pascher A; Plöckinger U; Gress TM; Wurst C; Weber F; Raffel A; Krausch M; Holzer K; Bartsch DK; Musholt TJ; Keck T; Anlauf M; Rinke A; Pape UF; Goretzki PE;
    Langenbecks Arch Surg; 2020 Mar; 405(2):145-154. PubMed ID: 32372309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?
    Merola E; Rinke A; Partelli S; Gress TM; Andreasi V; Kollár A; Perren A; Christ E; Panzuto F; Pascher A; Jann H; Arsenic R; Cremer B; Kaemmerer D; Kump P; Lipp RW; Agaimy A; Wiedenmann B; Falconi M; Pavel ME
    Ann Surg Oncol; 2020 May; 27(5):1348-1355. PubMed ID: 31720931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms.
    Pommergaard HC; Nielsen K; Sorbye H; Federspiel B; Tabaksblat EM; Vestermark LW; Janson ET; Hansen CP; Ladekarl M; Garresori H; Hjortland GO; Sundlöv A; Galleberg R; Knigge P; Kjaer A; Langer SW; Knigge U
    J Neuroendocrinol; 2021 May; 33(5):e12967. PubMed ID: 33769624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Margin status and long-term prognosis of primary pancreatic neuroendocrine tumor after curative resection: Results from the US Neuroendocrine Tumor Study Group.
    Zhang XF; Wu Z; Cloyd J; Lopez-Aguiar AG; Poultsides G; Makris E; Rocha F; Kanji Z; Weber S; Fisher A; Fields R; Krasnick BA; Idrees K; Smith PM; Cho C; Beems M; Schmidt CR; Dillhoff M; Maithel SK; Pawlik TM
    Surgery; 2019 Mar; 165(3):548-556. PubMed ID: 30278986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.
    Deng BY; Liu F; Yin SN; Chen AP; Xu L; Li B
    Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):261-268. PubMed ID: 29307515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does surgery provide a survival advantage in non-disseminated poorly differentiated gastroenteropancreatic neuroendocrine neoplasms?
    Thornblade LW; Warner SG; Melstrom L; Ituarte PHG; Chang S; Li D; Fong Y; Singh G
    Surgery; 2021 Jun; 169(6):1417-1423. PubMed ID: 33637345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations.
    Russolillo N; Vigano' L; Razzore P; Langella S; Motta M; Bertuzzo F; Papotti M; Ferrero A
    Eur J Surg Oncol; 2015 Jun; 41(6):751-7. PubMed ID: 25887286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic neuroendocrine tumors: A single-center 20-year experience with 100 patients.
    Shiba S; Morizane C; Hiraoka N; Sasaki M; Koga F; Sakamoto Y; Kondo S; Ueno H; Ikeda M; Yamada T; Shimada K; Kosuge T; Okusaka T
    Pancreatology; 2016; 16(1):99-105. PubMed ID: 26718527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimodality management, recurrence patterns, and long-term outcome of gastroenteropancreatic neuroendocrine neoplasms: Progress over 17 years.
    Desai GS; Pande P; Chhabra V; Shah RC; Jagannath P
    Indian J Gastroenterol; 2019 Oct; 38(5):399-410. PubMed ID: 31802438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinicopathologic characteristics and prognosis of rectal neuroendocrine neoplasms].
    Liu T; Liu P; Wu T; Pan Y; Chen G; Wang P; Jiang Y; Wu Y; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1015-1019. PubMed ID: 28900992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving survival prognostication of gastroenteropancreatic neuroendocrine neoplasms: Revised staging criteria.
    Martin JA; Warner RR; Wisnivesky JP; Kim MK
    Eur J Cancer; 2017 May; 76():197-204. PubMed ID: 28334622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival Analyses for Patients With Surgically Resected Pancreatic Neuroendocrine Tumors by World Health Organization 2010 Grading Classifications and American Joint Committee on Cancer 2010 Staging Systems.
    Yang M; Ke NW; Zhang Y; Zeng L; Tan CL; Zhang H; Mai G; Tian BL; Liu XB
    Medicine (Baltimore); 2015 Dec; 94(48):e2156. PubMed ID: 26632896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the World Health Organization 2010 grading system in surgical outcome and prognosis of pancreatic neuroendocrine tumors.
    Yang M; Tian BL; Zhang Y; Su AP; Yue PJ; Xu S; Wang L
    Pancreas; 2014 Oct; 43(7):1003-8. PubMed ID: 24945681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of surgery for pancreatic neuroendocrine neoplasms.
    Fischer L; Bergmann F; Schimmack S; Hinz U; Prieß S; Müller-Stich BP; Werner J; Hackert T; Büchler MW
    Br J Surg; 2014 Oct; 101(11):1405-12. PubMed ID: 25132004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail.
    Hank T; Hinz U; Tarantino I; Kaiser J; Niesen W; Bergmann F; Hackert T; Büchler MW; Strobel O
    Br J Surg; 2018 Aug; 105(9):1171-1181. PubMed ID: 29738626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resectability of primary gastroenteropancreatic neuroendocrine tumor as a prognostic factor for survival.
    Medrano-Guzmán R; López-García SC; Torres-Vargas S; González-Rodríguez D; Alvarado-Cabrero I
    Cir Cir; 2011; 79(6):498-504. PubMed ID: 22169366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnostics and therapy for neuroendocrine neoplasia of an unknown primary - a plea for open exploration].
    Begum N; Hubold C; Buchmann I; Thorns C; Bouchard R; Lubienski A; Schlöricke E; Zimmermann M; Lehnert H; Bruch HP; Bürk CG
    Zentralbl Chir; 2014 Jun; 139(3):284-91. PubMed ID: 23508839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neuroendocrine tumours of the GI tract--data from the German NET Registry].
    Begum N; Maasberg S; Plöckinger U; Anlauf M; Rinke A; Pöpperl G; Lehnert H; Izbicki JR; Krausch M; Vashist YK; Raffel A; Bürk CG; Hoffmann J; Goretzki P; Pape UF;
    Zentralbl Chir; 2014 Jun; 139(3):276-83. PubMed ID: 23042103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complications of surgery for gastro-entero-pancreatic neuroendocrine neoplasias.
    Albers MB; Almquist M; Bergenfelz A; Nordenström E
    Langenbecks Arch Surg; 2020 Mar; 405(2):137-143. PubMed ID: 32291468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.